Targeting the NLRP3 inflammasome in psoriasis
The NLRP3 inflammasome, a complex consisting of the nucleotide‐binding oligomerization domain, leucine‐rich repeat, and pyrin domain‐containing protein 3, has emerged as a critical mediator of pathological inflammation and a significant therapeutic target for various inflammatory diseases. Psoriasis...
Gespeichert in:
| Veröffentlicht in: | International journal of dermatology 2024-07, Vol.63 (7), p.844-851 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 851 |
|---|---|
| container_issue | 7 |
| container_start_page | 844 |
| container_title | International journal of dermatology |
| container_volume | 63 |
| creator | Chen, Xiuhui Deng, Guoliang Chen, Kaifeng Chen, Yanhong Ye, Weijun Sun, Ping |
| description | The NLRP3 inflammasome, a complex consisting of the nucleotide‐binding oligomerization domain, leucine‐rich repeat, and pyrin domain‐containing protein 3, has emerged as a critical mediator of pathological inflammation and a significant therapeutic target for various inflammatory diseases. Psoriasis, a chronic inflammatory skin condition without a definitive cure, has shown promising results in animal models through the inhibition of the NLRP3 inflammasome. This review aims to explore the development of the NLRP3 inflammasome in psoriasis and the molecular mechanisms responsible for its inhibition by natural products and small molecules currently being developed for psoriasis treatment. Furthermore, we are examining clinical trials using agents that block the NLRP3 pathway for the treatment of psoriasis. This study is timely to provide a new perspective on managing psoriasis. |
| doi_str_mv | 10.1111/ijd.17073 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2926076948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2926076948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3133-83490f9500c29eef5cd345b4dae80b1d4b13d8cbca9759fce1f7b6fb3169c5993</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlYP_gFZ8KKHbZOdZHdzlPpVKSpSzyGbTWrKftSki_TfG93qQXAuwwsPzwwvQqcEj0mYiV2VY5LhDPbQkEDKYppCso-GGBMSc8z4AB15vwoREkIP0QByoCwDOkTxQrql3thmGW3edPQ4f3mGyDamknUtfVvrEKK1b52V3vpjdGBk5fXJbo_Q6-3NYnofz5_uZtOreayAAMTBzrHhDGOVcK0NU2W4V9BS6hwXpKQFgTJXhZI8Y9woTUxWpKYAknLFOIcRuui9a9e-d9pvRG290lUlG912XiQ8SXGWcpoH9PwPumo714TvBOCMsRwHMlCXPaVc673TRqydraXbCoLFV4cidCi-Owzs2c7YFbUuf8mf0gIw6YEPW-nt_yYxe7julZ91M3iM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3075580607</pqid></control><display><type>article</type><title>Targeting the NLRP3 inflammasome in psoriasis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chen, Xiuhui ; Deng, Guoliang ; Chen, Kaifeng ; Chen, Yanhong ; Ye, Weijun ; Sun, Ping</creator><creatorcontrib>Chen, Xiuhui ; Deng, Guoliang ; Chen, Kaifeng ; Chen, Yanhong ; Ye, Weijun ; Sun, Ping</creatorcontrib><description>The NLRP3 inflammasome, a complex consisting of the nucleotide‐binding oligomerization domain, leucine‐rich repeat, and pyrin domain‐containing protein 3, has emerged as a critical mediator of pathological inflammation and a significant therapeutic target for various inflammatory diseases. Psoriasis, a chronic inflammatory skin condition without a definitive cure, has shown promising results in animal models through the inhibition of the NLRP3 inflammasome. This review aims to explore the development of the NLRP3 inflammasome in psoriasis and the molecular mechanisms responsible for its inhibition by natural products and small molecules currently being developed for psoriasis treatment. Furthermore, we are examining clinical trials using agents that block the NLRP3 pathway for the treatment of psoriasis. This study is timely to provide a new perspective on managing psoriasis.</description><identifier>ISSN: 0011-9059</identifier><identifier>ISSN: 1365-4632</identifier><identifier>EISSN: 1365-4632</identifier><identifier>DOI: 10.1111/ijd.17073</identifier><identifier>PMID: 38345734</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animal models ; Animals ; Biological Products - pharmacology ; Biological Products - therapeutic use ; Clinical trials ; Dermatologic Agents - pharmacology ; Dermatologic Agents - therapeutic use ; Health services ; Humans ; Inflammasomes ; Inflammasomes - antagonists & inhibitors ; Inflammasomes - drug effects ; Inflammasomes - immunology ; Inflammasomes - metabolism ; Inflammatory diseases ; Leucine ; Molecular modelling ; Molecular Targeted Therapy - methods ; Natural products ; NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors ; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism ; Nucleotides ; Oligomerization ; Psoriasis ; Psoriasis - drug therapy ; Psoriasis - immunology ; Pyrin protein ; Signal Transduction - drug effects ; Skin diseases ; Therapeutic targets</subject><ispartof>International journal of dermatology, 2024-07, Vol.63 (7), p.844-851</ispartof><rights>2024 the International Society of Dermatology.</rights><rights>International Journal of Dermatology © 2024 International Society of Dermatology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3133-83490f9500c29eef5cd345b4dae80b1d4b13d8cbca9759fce1f7b6fb3169c5993</cites><orcidid>0009-0003-6834-9292</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fijd.17073$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fijd.17073$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38345734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Xiuhui</creatorcontrib><creatorcontrib>Deng, Guoliang</creatorcontrib><creatorcontrib>Chen, Kaifeng</creatorcontrib><creatorcontrib>Chen, Yanhong</creatorcontrib><creatorcontrib>Ye, Weijun</creatorcontrib><creatorcontrib>Sun, Ping</creatorcontrib><title>Targeting the NLRP3 inflammasome in psoriasis</title><title>International journal of dermatology</title><addtitle>Int J Dermatol</addtitle><description>The NLRP3 inflammasome, a complex consisting of the nucleotide‐binding oligomerization domain, leucine‐rich repeat, and pyrin domain‐containing protein 3, has emerged as a critical mediator of pathological inflammation and a significant therapeutic target for various inflammatory diseases. Psoriasis, a chronic inflammatory skin condition without a definitive cure, has shown promising results in animal models through the inhibition of the NLRP3 inflammasome. This review aims to explore the development of the NLRP3 inflammasome in psoriasis and the molecular mechanisms responsible for its inhibition by natural products and small molecules currently being developed for psoriasis treatment. Furthermore, we are examining clinical trials using agents that block the NLRP3 pathway for the treatment of psoriasis. This study is timely to provide a new perspective on managing psoriasis.</description><subject>Animal models</subject><subject>Animals</subject><subject>Biological Products - pharmacology</subject><subject>Biological Products - therapeutic use</subject><subject>Clinical trials</subject><subject>Dermatologic Agents - pharmacology</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Health services</subject><subject>Humans</subject><subject>Inflammasomes</subject><subject>Inflammasomes - antagonists & inhibitors</subject><subject>Inflammasomes - drug effects</subject><subject>Inflammasomes - immunology</subject><subject>Inflammasomes - metabolism</subject><subject>Inflammatory diseases</subject><subject>Leucine</subject><subject>Molecular modelling</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Natural products</subject><subject>NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors</subject><subject>NLR Family, Pyrin Domain-Containing 3 Protein - metabolism</subject><subject>Nucleotides</subject><subject>Oligomerization</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - immunology</subject><subject>Pyrin protein</subject><subject>Signal Transduction - drug effects</subject><subject>Skin diseases</subject><subject>Therapeutic targets</subject><issn>0011-9059</issn><issn>1365-4632</issn><issn>1365-4632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LAzEQhoMotlYP_gFZ8KKHbZOdZHdzlPpVKSpSzyGbTWrKftSki_TfG93qQXAuwwsPzwwvQqcEj0mYiV2VY5LhDPbQkEDKYppCso-GGBMSc8z4AB15vwoREkIP0QByoCwDOkTxQrql3thmGW3edPQ4f3mGyDamknUtfVvrEKK1b52V3vpjdGBk5fXJbo_Q6-3NYnofz5_uZtOreayAAMTBzrHhDGOVcK0NU2W4V9BS6hwXpKQFgTJXhZI8Y9woTUxWpKYAknLFOIcRuui9a9e-d9pvRG290lUlG912XiQ8SXGWcpoH9PwPumo714TvBOCMsRwHMlCXPaVc673TRqydraXbCoLFV4cidCi-Owzs2c7YFbUuf8mf0gIw6YEPW-nt_yYxe7julZ91M3iM</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Chen, Xiuhui</creator><creator>Deng, Guoliang</creator><creator>Chen, Kaifeng</creator><creator>Chen, Yanhong</creator><creator>Ye, Weijun</creator><creator>Sun, Ping</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0003-6834-9292</orcidid></search><sort><creationdate>202407</creationdate><title>Targeting the NLRP3 inflammasome in psoriasis</title><author>Chen, Xiuhui ; Deng, Guoliang ; Chen, Kaifeng ; Chen, Yanhong ; Ye, Weijun ; Sun, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3133-83490f9500c29eef5cd345b4dae80b1d4b13d8cbca9759fce1f7b6fb3169c5993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Biological Products - pharmacology</topic><topic>Biological Products - therapeutic use</topic><topic>Clinical trials</topic><topic>Dermatologic Agents - pharmacology</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Health services</topic><topic>Humans</topic><topic>Inflammasomes</topic><topic>Inflammasomes - antagonists & inhibitors</topic><topic>Inflammasomes - drug effects</topic><topic>Inflammasomes - immunology</topic><topic>Inflammasomes - metabolism</topic><topic>Inflammatory diseases</topic><topic>Leucine</topic><topic>Molecular modelling</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Natural products</topic><topic>NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors</topic><topic>NLR Family, Pyrin Domain-Containing 3 Protein - metabolism</topic><topic>Nucleotides</topic><topic>Oligomerization</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - immunology</topic><topic>Pyrin protein</topic><topic>Signal Transduction - drug effects</topic><topic>Skin diseases</topic><topic>Therapeutic targets</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Xiuhui</creatorcontrib><creatorcontrib>Deng, Guoliang</creatorcontrib><creatorcontrib>Chen, Kaifeng</creatorcontrib><creatorcontrib>Chen, Yanhong</creatorcontrib><creatorcontrib>Ye, Weijun</creatorcontrib><creatorcontrib>Sun, Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Xiuhui</au><au>Deng, Guoliang</au><au>Chen, Kaifeng</au><au>Chen, Yanhong</au><au>Ye, Weijun</au><au>Sun, Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting the NLRP3 inflammasome in psoriasis</atitle><jtitle>International journal of dermatology</jtitle><addtitle>Int J Dermatol</addtitle><date>2024-07</date><risdate>2024</risdate><volume>63</volume><issue>7</issue><spage>844</spage><epage>851</epage><pages>844-851</pages><issn>0011-9059</issn><issn>1365-4632</issn><eissn>1365-4632</eissn><abstract>The NLRP3 inflammasome, a complex consisting of the nucleotide‐binding oligomerization domain, leucine‐rich repeat, and pyrin domain‐containing protein 3, has emerged as a critical mediator of pathological inflammation and a significant therapeutic target for various inflammatory diseases. Psoriasis, a chronic inflammatory skin condition without a definitive cure, has shown promising results in animal models through the inhibition of the NLRP3 inflammasome. This review aims to explore the development of the NLRP3 inflammasome in psoriasis and the molecular mechanisms responsible for its inhibition by natural products and small molecules currently being developed for psoriasis treatment. Furthermore, we are examining clinical trials using agents that block the NLRP3 pathway for the treatment of psoriasis. This study is timely to provide a new perspective on managing psoriasis.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>38345734</pmid><doi>10.1111/ijd.17073</doi><tpages>8</tpages><orcidid>https://orcid.org/0009-0003-6834-9292</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0011-9059 |
| ispartof | International journal of dermatology, 2024-07, Vol.63 (7), p.844-851 |
| issn | 0011-9059 1365-4632 1365-4632 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2926076948 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animal models Animals Biological Products - pharmacology Biological Products - therapeutic use Clinical trials Dermatologic Agents - pharmacology Dermatologic Agents - therapeutic use Health services Humans Inflammasomes Inflammasomes - antagonists & inhibitors Inflammasomes - drug effects Inflammasomes - immunology Inflammasomes - metabolism Inflammatory diseases Leucine Molecular modelling Molecular Targeted Therapy - methods Natural products NLR Family, Pyrin Domain-Containing 3 Protein - antagonists & inhibitors NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Nucleotides Oligomerization Psoriasis Psoriasis - drug therapy Psoriasis - immunology Pyrin protein Signal Transduction - drug effects Skin diseases Therapeutic targets |
| title | Targeting the NLRP3 inflammasome in psoriasis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A29%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20the%20NLRP3%20inflammasome%20in%20psoriasis&rft.jtitle=International%20journal%20of%20dermatology&rft.au=Chen,%20Xiuhui&rft.date=2024-07&rft.volume=63&rft.issue=7&rft.spage=844&rft.epage=851&rft.pages=844-851&rft.issn=0011-9059&rft.eissn=1365-4632&rft_id=info:doi/10.1111/ijd.17073&rft_dat=%3Cproquest_cross%3E2926076948%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3075580607&rft_id=info:pmid/38345734&rfr_iscdi=true |